Patient Support Program (PSP) snapshot — access, reimbursement, enrollment, and coordinator coverage for COMPASS (OCREVUS + ENSPRYNG). Figures roll up nightly from Snowflake; NCM queue is near real-time.
Revenue at risk
$2.1M
34 patients · dropout risk >75
Action required
Invoice exceptions
$47,200
8 of 117 invoices flagged
Review needed
OCREVUS persistence (12M)
68%
vs 74% benchmark ↓
Below target
Cost per persistent patient
$3,847
vs $3,200 target ↑
Above budget
12-month persistence — OCREVUS vs ENSPRYNG
OCREVUSENSPRYNGBenchmark (74%)
Alerts3 critical
34 OCREVUS patients — no NCM contact 30+ days. $2.1M at risk.
Today · View
McKesson drug-to-appointment: 91% vs 95% target. 3 infusions at risk.
417 patients · Jan 2024 – Mar 2026 · CDA-AMC 2025 format · De-identified
ENSPRYNG injection training outcomes · rare disease
89 patients · AQP4-positive · PRO assessments at 6M/12M
Provincial reimbursement outcomes · RAMQ vs private
All 10 provinces · PA cycle time comparison · Denial rate by province
Recent report runsLast 24 hours
QC missed infusion risk cohort
Triggered from Cortex Analyst query
Done
RAMQ PA cycle time trend
Scheduled weekly dashboard refresh
Done
CADTH evidence package (OCREVUS)
Needs chapter lead sign-off
Review
Program Management/OCREVUS + ENSPRYNGLiveMar 30, 2026
Program operations hub
Enrollment, authorization, access barriers, and persistence outcomes across active brands.
2 active programs34 high-risk patientsWeekly review
OCREVUS (ocrelizumab)
IV Infusion · q26 weeks · ~$30,000/patient/year
Enrolled417 · 389 active
12M persistence68% ↓ (74% benchmark)
PA first-pass71% (82% benchmark)
Time to first infusion11.2 days (<8 target)
Monthly PSP cost$187,400 · $482/patient
NCM caseload156 (150 target)
ENSPRYNG (satralizumab)
SC Self-Injection · ~$70,000/patient/year
Enrolled89 · 84 active
12M persistence79% ↑ (74% benchmark)
PA first-pass84% (82% benchmark)
Time to first training6.4 days (<7 target)
Monthly PSP cost$38,200 · $455/patient
NCM caseload89 (150 target)
OCREVUS — top priority patients this week34 total · sorted by risk score
Patient
Province
Risk score
Last contact
Status
Action
M.T.
QC
91 High
31 days ago
PA renewal overdue
View
R.L.
ON
87 High
22 days ago
Infusion no-show
Contact
J.B.
BC
74 Med
18 days ago
Supply delay flagged
Escalate
A.K.
ON
71 Med
15 days ago
Financial barrier
PAP referral
P.D.
AB
65 Low-med
12 days ago
Adherence declining
Check-in
Projected month-end enrollments
522
Range: 516-529 based on current intake
PA conversion (rolling 30d)
78%
Target >80% by Q2
Coordinator capacity
104%
3 users above target caseload
Access bottlenecks by provinceRolling 30 days
Province
PA pending
Avg cycle
Denial %
Main blocker
QC (RAMQ)
28
14.2d
12%
Missing MRI + EDSS updates
ON
19
10.8d
8%
Prior authorization docs incomplete
BC
9
8.6d
5%
Special authority backlog
AB + Atlantic
5
7.9d
3%
Low volume / payer variance
Program action trackerThis week
High-risk OCREVUS outreach campaign
34 patients targeted · bilingual scripts ready
In progress
ENSPRYNG training confirmation sync
Nurse network to Salesforce write-back validation
On track
PA template update (RAMQ)
MNI-required evidence fields added
Completed
NCM load balancing
3 coordinators above threshold
Needs action
Patient 360/Marie T. · OCREVUS · QCLiveMar 30, 2026
Programs›OCREVUS›Marie T.
Case PSP-OC-QC-2024-08421Last synced Mar 30, 2026 · Salesforce · Snowflake PHI view
MT
Marie T.
OCREVUS (ocrelizumab) · Enrolled Mar 14, 2024 · COMPASS mobile app
QCFR preferredNBA 91Case open
91
High dropout risk · Immediate outreach
4Infusions
31dSince NCM
Apr 12Next due
Demographics & coverage
Age34
ProvinceQuebec (RAMQ)
DiagnosisRRMS
Treating HCPDr. I. Moreau · Montreal Neurological Institute
InsuranceRAMQ + Sun Life (eBV verified)
LanguageFrench
Infusion siteToronto General Hospital
Risk drivers
▸ PA renewal overdue 12 days vs plan ▸ Last NCM contact 31 days ago (SLA: 14 days) ▸ RAMQ documentation gap — MRI + EDSS pending from MNI
PA & benefitsRAMQ · Sun Life
Public plan authorizationLapsed
Coverage ended Mar 1, 2026. Renewal package not submitted — blocks next infusion billing.
Private plan PAActive
PAP / copay cardEnrolled · $2,400 YTD
eBV last refreshMar 28, 2026
Care team
IM
Dr. Isabelle Moreau
Neurologist · Prescriber · MNI
NC
Nadia C. · NCM
Primary coordinator · COMPASS PSP
PH
Pharmacy liaison · McKesson
Supply & cold chain · Last note Mar 4
Infusion & scheduleOCREVUS IV · q26 weeks
Next infusion · Apr 12, 2026
Toronto General · Day unit · Pre-meds per protocol
At risk — PA gap
Last completed
Feb 3, 2026
Cycle
Infusion #5
Days since dose
55d
IRR history
None recorded
RescheduleView clinic instructionsMcKesson order status
Journey timelineClinical & PSP events
Mar 6, 2026
PA renewal overdue
RAMQ documentation gap — no submission yet
Feb 3, 2026
Infusion #4 attended
Toronto General · McKesson supply confirmed · No IRR
Jan 15, 2026
NCM phone call
Tolerability confirmed · Next infusion scheduled
Dec 19, 2025
Infusion #3 attended
No issues
Nov 28, 2025
RAMQ renewal approved
Submitted Nov 28 · Approved Dec 9
Mar 14, 2024
Enrolled via COMPASS App
Consent · Case opened · Infusion site confirmed
Open tasksCoordinator checklist
AI-recommended next action
Marie's PA with RAMQ expired March 1. Renewal requires updated EDSS and MRI from Dr. Moreau at MNI. Prior year data pre-loaded. NCM outreach in French recommended within 24 hours.
Coordinator Workspace/NCM Daily Queue · NBA Actions · Case NotesLiveMar 30, 2026
Daily execution center
Prioritized outreach queue with AI scripts, SLA tracking, and escalation routing.
Morning shift active12 due today3 SLA breaches
My open cases
47
12 require action today
SLA breaches
3
Overdue >7 days
AI actions completed today
8
PA drafts · outreach scripts
Priority queue — sorted by NBA risk score
Queue list view8/12 operational scan
Patient
Province
Program
Risk
Last contact
Primary blocker
Next action
Owner
Marie T.
QC
OCREVUS
91
31d
RAMQ PA expired
NCM FR call + PA draft
Nadia C.
R.L.
ON
OCREVUS
87
22d
Missed infusion
Call + reschedule
Owen P.
J.B.
BC
OCREVUS
74
18d
Drug delivery delay
Escalate McKesson
Nadia C.
A.K.
ON
OCREVUS
71
15d
Copay gap
PAP referral
Ishaan M.
P.D.
AB
OCREVUS
65
12d
Adherence decline
Check-in + reminder
Ishaan M.
L.P.
QC
ENSPRYNG
72
14d
Training not confirmed
Verify completion
Marina R.
S.N.
ON
OCREVUS
69
11d
Clinic slot not booked
Book infusion date
Owen P.
D.K.
MB
ENSPRYNG
63
9d
PA docs incomplete
Collect lab panel
Marina R.
Queue total
47
12 due today
High risk (>80)
9
Priority outreach first
SLA at risk
6
No contact >14 days
Upcoming due actions (next 24h)
Marie T. · QC
PA package + FR callback before 2:00 PM
Urgent
R.L. · ON
No-show rescue call + clinic rebook
Today
L.P. · QC
Training completion confirmation pending
Today
91
Marie T. · QC · OCREVUS PA overdue
Last contact: 31 days ago · RAMQ PA expired Mar 1 · Dr. Moreau at MNI
AI script (FR): "Bonjour Marie, je vous appelle au sujet du renouvellement de votre autorisation RAMQ pour OCREVUS. Nous avons besoin d'un rapport IRM récent de Dr. Moreau..."
87
R.L. · ON · OCREVUS No-show
Last contact: 22 days ago · Missed infusion Feb 28 at Ottawa Infusion Centre · No IRR history
AI script (EN): "Hi Robert, this is your nurse care manager at COMPASS. We noticed you missed your OCREVUS infusion on February 28th. I wanted to check in..."
74
J.B. · BC · OCREVUS Supply delay
Last contact: 18 days ago · McKesson shipment delayed 3 days vs infusion at VGH · Cold chain OK
71
A.K. · ON · OCREVUS Financial barrier
Last contact: 15 days ago · AI detected financial barrier in last NCM note · Sun Life co-pay gap identified
AI insight: Patient mentioned "cost concerns" in last interaction. Eligible for PAP co-pay card. Estimated annual benefit: $2,400.
